- Record: found
- Abstract: not found
- Article: not found
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman ,
Christoph Wanner ,
John M. Lachin ,
David Fitchett ,
Erich Bluhmki ,
Stefan Hantel ,
Michaela Mattheus ,
Theresa Devins ,
Odd Erik Johansen ,
Hans J. Woerle ,
Uli C. Broedl ,
Silvio E. Inzucchi
November 26 2015
November 26 2015
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition
to standard care, on cardiovascular morbidity and mortality in patients with type
2 diabetes at high cardiovascular risk are not known.